HIV Infections Clinical Trial
Official title:
Effectiveness of a Video-based Educational Intervention to Prevent Human Immunodeficiency Virus (HIV) and Sexually Transmitted Diseases (STDs) Among Patients Attending STD Clinics
The purpose of this study is to assess the effectiveness of a brief 23-minute video-based educational waiting room intervention to reduce incident STD and high risk behavior among STD patients attending STD clinics in three United States (U.S.) cities.
Approximately 15 million incident cases of sexually transmitted diseases (STDs) occur
annually. As a result, primary prevention of HIV/STDs among persons who have chosen to be
sexually active remains a high public health priority. A number of effective interventions
to prevent HIV/STDs have been developed, however many require considerable time and resource
investments from both service providers and participants. These programs are often difficult
to implement and sustain over time. As a result, simple practical interventions that can
reduce transmission or acquisition of HIV/STDs among STD clinic patients while being both
easily implemented and sustainable are urgently needed, and will ultimately enhance the menu
of effective programs that are currently available to the STD clinic population.
The intervention trial was designed to develop and evaluate a video-based HIV/STD prevention
intervention for STD clinic clients. The primary goals of this study are to assess whether a
brief video-based educational waiting room intervention can reduce STD incidence (STD
incidence outcome study) and high risk behavior (behavioral outcome study) among male and
female patients attending STD clinics, when compared with patients who receive standard
clinic services. This study is being conducted as a multi-site trial in 3 urban STD clinics.
The intervention condition consists of a 23-minute educational video focused on preventing
STD and HIV infection shown on a large television in the waiting room. Health promotion
posters supplement the video. The control condition consists of the current standard waiting
room experience in each city's STD clinic.
In the STD incidence outcome study, groups of patients attending the participating STD
clinics are randomly assigned to blocks of clinic weeks to either the intervention or
control condition. A waiver of informed consent was obtained whereby no subjects are
actively enrolled for this phase of the study. Through a retrospective review of existing
medical records and STD surveillance registry data, we will determine and compare the
incidence of new STDs over a 12-month period (on average) by assigned waiting room
conditions.
In the behavioral outcome study, investigators administer computer-based survey instruments
to a random sample of ~1600 male and female patients (800 per arm) both at enrollment and at
3 months following their initial clinic visit. The primary objective of the behavioral study
is to assess the effectiveness of the video intervention by comparing levels of high-risk
behavior between waiting room conditions at 3 months' follow-up.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |